(News Bulletin 247) – AstraZeneca yesterday published the results of its TROPION-Lung01 trial evaluating datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with non-small cell lung cancer after first-line treatment.
‘Unfortunately, the trial would have shown Grade 5 events (i.e. leading to the death of the patient). No new safety problem has been observed with respect to previous trials, which could lead us to think of pulmonary infections,” underlines Oddo BHF. After this news, the title lost almost 8% at the end of the session.
‘ The lack of qualitative commentary obviously does not help to form an opinion. It is explained all the same, in our opinion, in two ways: i/ the large population of the trial which without any doubt will have to be stratified to see a strong clinical efficacy and ii/ unfortunately the appearance of Grade 5. Only the complete results will be able to anticipate the development of the drug in earlier lines (1L in combination with Imfinzi)’ believes Oddo BHF.
Oddo confirms its Outperformance recommendation with a price target lowered from 450p to 13800p.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
